Selected research
Industry Research
Human Chorionic Gonadotropin (HCG) Industry Research Report 2026
Market perspective
The global Human Chorionic Gonadotropin (HCG) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Human Chorionic Gonadotropin (HCG) market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Human Chorionic Gonadotropin (HCG) market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Human Chorionic Gonadotropin (HCG) market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Human Chorionic Gonadotropin (HCG) include Sun Pharmaceutical Industries Ltd, Ferring B.V, Fresenius Kabi AG, Zydus Lifesciences Ltd, VHB Medi Sciences Limited, Serum Institute of India Pvt. Ltd, Scripps Laboratories, Sanzyme and Merck & Co., Inc, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Human Chorionic Gonadotropin (HCG) market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Human Chorionic Gonadotropin (HCG).
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Human Chorionic Gonadotropin (HCG) Market by Company
Sun Pharmaceutical Industries Ltd
Ferring B.V
Fresenius Kabi AG
Zydus Lifesciences Ltd
VHB Medi Sciences Limited
Serum Institute of India Pvt. Ltd
Scripps Laboratories
Sanzyme
Merck & Co., Inc
LUPIN
Leebio
Kamiya Biomedical Company
EMD Serono, Inc
Corona Remedies Pvt. Ltd.
Cigna
Bristol Myers Squibb Company
Human Chorionic Gonadotropin (HCG) Segment by Type
Natural Source Extraction
Recombinant DNA Technology
Human Chorionic Gonadotropin (HCG) Segment by Application
Cryptorchidism Treatment
Oligospermic Treatment
Female Infertility Treatment
Others
Human Chorionic Gonadotropin (HCG) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Chorionic Gonadotropin (HCG) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Chorionic Gonadotropin (HCG) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Chorionic Gonadotropin (HCG).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Human Chorionic Gonadotropin (HCG) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Natural Source Extraction
- Recombinant DNA Technology
Applications
- Cryptorchidism Treatment
- Oligospermic Treatment
- Female Infertility Treatment
- Others
Companies covered
- Sun Pharmaceutical Industries Ltd
- Ferring B.V
- Fresenius Kabi AG
- Zydus Lifesciences Ltd
- VHB Medi Sciences Limited
- Serum Institute of India Pvt. Ltd
- Scripps Laboratories
- Sanzyme
- Merck & Co., Inc
- LUPIN
- Leebio
- Kamiya Biomedical Company
- EMD Serono, Inc
- Corona Remedies Pvt. Ltd.
- Cigna
- Bristol Myers Squibb Company
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Human Chorionic Gonadotropin (HCG) by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Natural Source Extraction
- 2.2.3 Recombinant DNA Technology
- 2.3 Human Chorionic Gonadotropin (HCG) by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cryptorchidism Treatment
- 2.3.3 Oligospermic Treatment
- 2.3.4 Female Infertility Treatment
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Human Chorionic Gonadotropin (HCG) Breakdown Data by Type
- 3.1 Global Human Chorionic Gonadotropin (HCG) Historic Market Size by Type (2021-2026)
- 3.2 Global Human Chorionic Gonadotropin (HCG) Forecasted Market Size by Type (2027-2032)
4 Human Chorionic Gonadotropin (HCG) Breakdown Data by Application
- 4.1 Global Human Chorionic Gonadotropin (HCG) Historic Market Size by Application (2021-2026)
- 4.2 Global Human Chorionic Gonadotropin (HCG) Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Human Chorionic Gonadotropin (HCG) Market Perspective (2021-2032)
- 5.2 Global Human Chorionic Gonadotropin (HCG) Growth Trends by Region
- 5.2.1 Global Human Chorionic Gonadotropin (HCG) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Human Chorionic Gonadotropin (HCG) Historic Market Size by Region (2021-2026)
- 5.2.3 Human Chorionic Gonadotropin (HCG) Forecasted Market Size by Region (2027-2032)
- 5.3 Human Chorionic Gonadotropin (HCG) Market Dynamics
- 5.3.1 Human Chorionic Gonadotropin (HCG) Industry Trends
- 5.3.2 Human Chorionic Gonadotropin (HCG) Market Drivers
- 5.3.3 Human Chorionic Gonadotropin (HCG) Market Challenges
- 5.3.4 Human Chorionic Gonadotropin (HCG) Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Human Chorionic Gonadotropin (HCG) Players by Revenue
- 6.1.1 Global Top Human Chorionic Gonadotropin (HCG) Players by Revenue (2021-2026)
- 6.1.2 Global Human Chorionic Gonadotropin (HCG) Revenue Market Share by Players (2021-2026)
- 6.2 Global Human Chorionic Gonadotropin (HCG) Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Human Chorionic Gonadotropin (HCG) Head Office and Area Served
- 6.4 Global Human Chorionic Gonadotropin (HCG) Players, Product Type & Application
- 6.5 Global Human Chorionic Gonadotropin (HCG) Manufacturers Established Date
- 6.6 Global Human Chorionic Gonadotropin (HCG) Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Human Chorionic Gonadotropin (HCG) Market Size (2021-2032)
- 7.2 North America Human Chorionic Gonadotropin (HCG) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Human Chorionic Gonadotropin (HCG) Market Size by Country (2021-2026)
- 7.4 North America Human Chorionic Gonadotropin (HCG) Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Human Chorionic Gonadotropin (HCG) Market Size (2021-2032)
- 8.2 Europe Human Chorionic Gonadotropin (HCG) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Human Chorionic Gonadotropin (HCG) Market Size by Country (2021-2026)
- 8.4 Europe Human Chorionic Gonadotropin (HCG) Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Human Chorionic Gonadotropin (HCG) Market Size (2021-2032)
- 9.2 Asia-Pacific Human Chorionic Gonadotropin (HCG) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Human Chorionic Gonadotropin (HCG) Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Human Chorionic Gonadotropin (HCG) Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Human Chorionic Gonadotropin (HCG) Market Size (2021-2032)
- 10.2 South America Human Chorionic Gonadotropin (HCG) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Human Chorionic Gonadotropin (HCG) Market Size by Country (2021-2026)
- 10.4 South America Human Chorionic Gonadotropin (HCG) Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Human Chorionic Gonadotropin (HCG) Market Size (2021-2032)
- 11.2 Middle East & Africa Human Chorionic Gonadotropin (HCG) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Human Chorionic Gonadotropin (HCG) Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Human Chorionic Gonadotropin (HCG) Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Sun Pharmaceutical Industries Ltd
- 12.1.1 Sun Pharmaceutical Industries Ltd Company Information
- 12.1.2 Sun Pharmaceutical Industries Ltd Business Overview
- 12.1.3 Sun Pharmaceutical Industries Ltd Revenue in Human Chorionic Gonadotropin (HCG) Business (2021-2026)
- 12.1.4 Sun Pharmaceutical Industries Ltd Human Chorionic Gonadotropin (HCG) Product Portfolio
- 12.1.5 Sun Pharmaceutical Industries Ltd Recent Developments
- 12.2 Ferring B.V
- 12.2.1 Ferring B.V Company Information
- 12.2.2 Ferring B.V Business Overview
- 12.2.3 Ferring B.V Revenue in Human Chorionic Gonadotropin (HCG) Business (2021-2026)
- 12.2.4 Ferring B.V Human Chorionic Gonadotropin (HCG) Product Portfolio
- 12.2.5 Ferring B.V Recent Developments
- 12.3 Fresenius Kabi AG
- 12.3.1 Fresenius Kabi AG Company Information
- 12.3.2 Fresenius Kabi AG Business Overview
- 12.3.3 Fresenius Kabi AG Revenue in Human Chorionic Gonadotropin (HCG) Business (2021-2026)
- 12.3.4 Fresenius Kabi AG Human Chorionic Gonadotropin (HCG) Product Portfolio
- 12.3.5 Fresenius Kabi AG Recent Developments
- 12.4 Zydus Lifesciences Ltd
- 12.4.1 Zydus Lifesciences Ltd Company Information
- 12.4.2 Zydus Lifesciences Ltd Business Overview
- 12.4.3 Zydus Lifesciences Ltd Revenue in Human Chorionic Gonadotropin (HCG) Business (2021-2026)
- 12.4.4 Zydus Lifesciences Ltd Human Chorionic Gonadotropin (HCG) Product Portfolio
- 12.4.5 Zydus Lifesciences Ltd Recent Developments
- 12.5 VHB Medi Sciences Limited
- 12.5.1 VHB Medi Sciences Limited Company Information
- 12.5.2 VHB Medi Sciences Limited Business Overview
- 12.5.3 VHB Medi Sciences Limited Revenue in Human Chorionic Gonadotropin (HCG) Business (2021-2026)
- 12.5.4 VHB Medi Sciences Limited Human Chorionic Gonadotropin (HCG) Product Portfolio
- 12.5.5 VHB Medi Sciences Limited Recent Developments
- 12.6 Serum Institute of India Pvt. Ltd
- 12.6.1 Serum Institute of India Pvt. Ltd Company Information
- 12.6.2 Serum Institute of India Pvt. Ltd Business Overview
- 12.6.3 Serum Institute of India Pvt. Ltd Revenue in Human Chorionic Gonadotropin (HCG) Business (2021-2026)
- 12.6.4 Serum Institute of India Pvt. Ltd Human Chorionic Gonadotropin (HCG) Product Portfolio
- 12.6.5 Serum Institute of India Pvt. Ltd Recent Developments
- 12.7 Scripps Laboratories
- 12.7.1 Scripps Laboratories Company Information
- 12.7.2 Scripps Laboratories Business Overview
- 12.7.3 Scripps Laboratories Revenue in Human Chorionic Gonadotropin (HCG) Business (2021-2026)
- 12.7.4 Scripps Laboratories Human Chorionic Gonadotropin (HCG) Product Portfolio
- 12.7.5 Scripps Laboratories Recent Developments
- 12.8 Sanzyme
- 12.8.1 Sanzyme Company Information
- 12.8.2 Sanzyme Business Overview
- 12.8.3 Sanzyme Revenue in Human Chorionic Gonadotropin (HCG) Business (2021-2026)
- 12.8.4 Sanzyme Human Chorionic Gonadotropin (HCG) Product Portfolio
- 12.8.5 Sanzyme Recent Developments
- 12.9 Merck & Co., Inc
- 12.9.1 Merck & Co., Inc Company Information
- 12.9.2 Merck & Co., Inc Business Overview
- 12.9.3 Merck & Co., Inc Revenue in Human Chorionic Gonadotropin (HCG) Business (2021-2026)
- 12.9.4 Merck & Co., Inc Human Chorionic Gonadotropin (HCG) Product Portfolio
- 12.9.5 Merck & Co., Inc Recent Developments
- 12.10 LUPIN
- 12.10.1 LUPIN Company Information
- 12.10.2 LUPIN Business Overview
- 12.10.3 LUPIN Revenue in Human Chorionic Gonadotropin (HCG) Business (2021-2026)
- 12.10.4 LUPIN Human Chorionic Gonadotropin (HCG) Product Portfolio
- 12.10.5 LUPIN Recent Developments
- 12.11 Leebio
- 12.11.1 Leebio Company Information
- 12.11.2 Leebio Business Overview
- 12.11.3 Leebio Revenue in Human Chorionic Gonadotropin (HCG) Business (2021-2026)
- 12.11.4 Leebio Human Chorionic Gonadotropin (HCG) Product Portfolio
- 12.11.5 Leebio Recent Developments
- 12.12 Kamiya Biomedical Company
- 12.12.1 Kamiya Biomedical Company Company Information
- 12.12.2 Kamiya Biomedical Company Business Overview
- 12.12.3 Kamiya Biomedical Company Revenue in Human Chorionic Gonadotropin (HCG) Business (2021-2026)
- 12.12.4 Kamiya Biomedical Company Human Chorionic Gonadotropin (HCG) Product Portfolio
- 12.12.5 Kamiya Biomedical Company Recent Developments
- 12.13 EMD Serono, Inc
- 12.13.1 EMD Serono, Inc Company Information
- 12.13.2 EMD Serono, Inc Business Overview
- 12.13.3 EMD Serono, Inc Revenue in Human Chorionic Gonadotropin (HCG) Business (2021-2026)
- 12.13.4 EMD Serono, Inc Human Chorionic Gonadotropin (HCG) Product Portfolio
- 12.13.5 EMD Serono, Inc Recent Developments
- 12.14 Corona Remedies Pvt. Ltd.
- 12.14.1 Corona Remedies Pvt. Ltd. Company Information
- 12.14.2 Corona Remedies Pvt. Ltd. Business Overview
- 12.14.3 Corona Remedies Pvt. Ltd. Revenue in Human Chorionic Gonadotropin (HCG) Business (2021-2026)
- 12.14.4 Corona Remedies Pvt. Ltd. Human Chorionic Gonadotropin (HCG) Product Portfolio
- 12.14.5 Corona Remedies Pvt. Ltd. Recent Developments
- 12.15 Cigna
- 12.15.1 Cigna Company Information
- 12.15.2 Cigna Business Overview
- 12.15.3 Cigna Revenue in Human Chorionic Gonadotropin (HCG) Business (2021-2026)
- 12.15.4 Cigna Human Chorionic Gonadotropin (HCG) Product Portfolio
- 12.15.5 Cigna Recent Developments
- 12.16 Bristol Myers Squibb Company
- 12.16.1 Bristol Myers Squibb Company Company Information
- 12.16.2 Bristol Myers Squibb Company Business Overview
- 12.16.3 Bristol Myers Squibb Company Revenue in Human Chorionic Gonadotropin (HCG) Business (2021-2026)
- 12.16.4 Bristol Myers Squibb Company Human Chorionic Gonadotropin (HCG) Product Portfolio
- 12.16.5 Bristol Myers Squibb Company Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst